NOX1416 in Diabetic Foot Ulcers

Phase 1, randomised, single-blind trial in diabetic foot ulcer (DFU) comparing NOX1416 and SOC with SOC (Standard of care) (2 arms). Primary endpoints: Number of subjects with a Methemoglobin >5% at 14 weeks and Incidence and severity of treatment-emergent adverse events at 16 weeks. Started Jun 2024; status: active, not recruiting.